Here, we assessed the predictive value of our cfDNA biomarkers at therapy baseline (i.e., CNVs and fragmentation features) alongside tumor tissue PD-L1 TPS, neutrophil-to-lymphocyte ratios (NLR), data from complete blood counts, and various clinical blood values (Supplementary Methods). This evidence concerns the gene CD274 and neoplasm.